Abstract:To the Editor: Systemic lupus erythematosus (SLE) is an autoimmune disease that tends to affect females of childbearing age. There are nearly 4 million people in China currently suffering from SLE, which can cause multiple organ damage in its early stages and seriously affect patients’ quality of life.[1,2] Menstrual disorders are common in SLE patients and vary from heavy menstrual bleeding to amenorrhea. The etiology of menstrual irregularities includes the disease activity itself, glucocorticoids (GCs) treatment, and the use of some immunosuppressants.[3] This multicenter, cross-sectional, web-based observational study investigated menstrual irregularity, pregnancy outcomes, and birth outcomes on SLE patients across China. The research was approved by the Ethics Committee of Peking University People's Hospital, China (No. 2019PHB253-01). The patients were informed that consent was implied with completion of the questionnaire, and the process was anonymous and voluntary. A total of 3964 SLE female patients ranging in age between 15 years and 49 years were recruited from 157 hospitals across China [Supplementary Figure 1, https://links.lww.com/CM9/B404]. The patients answered the standardized questionnaire via email or text message under the guidance of a rheumatologist over the phone. Clinical data were collected through questionnaires [Supplementary Materials, https://links.lww.com/CM9/B404], including basic features, menstruation after diagnosis, medications, marriage and fertility status, reproductive history, adverse pregnancy outcomes (APO), and adverse birth outcomes (ABO). The categorized variables were shown as frequency or percentage, and continuous variables were demonstrated as mean ± standard deviation. The Mann–Whitney and chi-squared tests were used to determine any statistical difference between the means and proportions of the two groups. The variables were tested for normality and homogeneity of variance before the Mann–Whitney and chi-squared tests were carried out. Univariate and multivariate logistic regression analyses were used to assess associations between clinical characteristics and menstruation, pregnancy, and neonatal outcomes. A 95% confidence interval (CI) was calculated to identify the independent variable in the binary logistic regression analysis. Differences were considered statistically significant when P < 0.05. Statistical Package for Social Sciences (SPSS 26.0, IBM Corp, Armonk, NY, USA) was used to analyze all data. The mean age of the participants was 30.42 ± 7.40 years. Of these patients, 75.55% experienced menstrual disorders, including light menstrual bleeding (48.99%), shortened menstrual bleeding (23.31%), prolonged menstrual bleeding (13.65%), amenorrhea (10.85%), and heavy menstrual bleeding (7.11%). The proportions of GCs, cyclophosphamide (CYC), and mycophenolate mofetil (MMF) in these patients were 55.17%, 27.22%, and 28.58%, respectively. The percentage of CYC in combination with GC and GC with MMF was 24.09% and 20.51%, respectively. Compared with patients who experienced normal menstruation, patients experiencing abnormal menstruation were older (31.17 ± 7.59 vs. 28.12 ± 6.25 years, P < 0.001), had a higher average body mass index (BMI) (21.69 ± 3.32 vs. 21.32 ± 3.46 kg/m2, P = 0.003), and experienced a longer disease duration (6.28 ± 5.49 vs. 5.38 ± 4.72 year, P < 0.001). The treatment of CYC (37.67% vs. 21.88%, P < 0.001), GCs (75.84% vs. 51.56%, P < 0.001), and MMF (39.67% vs. 21.35%, P < 0.001) were all significantly higher in patients with abnormal menstruation [Supplementary Table 1, https://links.lww.com/CM9/B404]. Binary logistic regression demonstrated that older patients (Odds ratio [OR]: 1.039, 95% CI: 1.016–1.062, P = 0.001), longer disease duration (OR: 1.041, 95% CI: 1.004–1.079, P = 0.029), CYC treatment (OR: 1.830, 95% CI: 1.273–2.630, P = 0.001), and GCs treatment (OR: 2.721, 95% CI: 2.008–3.686, P < 0.001) were independently related to menstrual disorders [Figure 1].Figure 1: Risk factors of menstrual disorders. ∗P < 0.05. BMI: Body Mass Index; CI: Confidence interval; CYC: Cyclophosphamide; GCs: Glucocorticoids; MMF: Mycophenolate Mofetil; SLE: Systemic lupus erythematosus.Among subjects with pregnancy history, the incidence of preterm delivery, miscarriage, fetal growth restriction, placental abruption, and hypertensive disease of pregnancy was 14.05%, 9.95%, 7.87%, 4.40%, and 2.26%, respectively [Supplementary Table 2, https://links.lww.com/CM9/B404]. There were no significant differences in age (34.83 ± 6.71 vs. 34.50 ± 6.61 years, P = 0.326), BMI (22.11 ± 3.18 vs. 22.21 ± 3.40 kg/m2, P = 0.558), disease duration (6.43 ± 5.37 vs. 6.06 ± 5.03 years, P = 0.146), history of CYC treatment (39.46% vs. 40.27%, P = 0.770), GCs treatment (73.70% vs. 72.86%, P = 0.739), or history of MMF treatment (38.00% vs. 35.15%, P = 0.295) between patients with and without APO [Supplementary Table 3, https://links.lww.com/CM9/B404]. Of the 1250 births in women, 70.48% were full-term normal births, 19.44% were born prematurely, 8.96% were small for gestational age neonates, 7.76% had neonatal pathological jaundice, and 1.44% had neonatal lupus. Patients in the ABO group were younger (32.59 ± 5.57 vs. 34.73 ± 6.52 years, P < 0.001) and experienced longer disease duration (7.53 ± 5.66 vs. 6.18 ± 5.02 years, P < 0.001) than patients without ABO. History of CYC treatment (24.39% vs. 48.03%, P < 0.001), GCs treatment (48.79% vs. 100%, P < 0.001), and MMF treatment (16.80% vs. 52.49%, P < 0.001) were significantly lower in the ABO group [Supplementary Table 4, https://links.lww.com/CM9/B404]. Binary logistic regression demonstrated that age (OR: 0.951, 95% CI: 0.912–0.991, P = 0.017) might be a protective factor associated with ABO. We conducted a large, cross-sectional study that investigated menstrual irregularity, pregnancy outcomes, and birth outcomes in SLE patients in China, and the results revealed that >75% of SLE patients experienced menstruation irregularity. Risk factors for menstrual irregularity included age, CYC treatment, and GCs treatment. This study found that age, BMI, disease duration, and treatment were not significantly associated with APO. The CYC, MMF, and GCs treatment may be associated with a low prevalence of ABO. Menstrual irregularity is common in SLE patients. In this study, nearly 50% of the patients experienced light menstrual bleeding, >20% of patients experienced shortened menstrual bleeding, and 10% experienced amenorrhea. This is consistent with previous studies.[4,5] Additionally, premature ovarian failure is associated with specific SLE-related autoantibodies (anti-Sm, anti-RNP, anti-cardiolipin, and lupus anticoagulant) and the use of immunosuppressants, particularly the use of CYC.[6,7] This study indicates that CYC treatment might be a risk factor for menstrual irregularity. Women with SLE have poorer maternal-fetal outcome compared with healthy individuals.[8] The rate of fetal loss has ranged from 3% to 43%. The rate of fetal loss in SLE pregnancies has decreased from an average of 43% to 17% over the past 40 years.[9] Disease flares, pregnancy loss, preeclampsia, preterm delivery, and intrauterine growth restrictions remain the primary complications during pregnancy.[10] This study has some limitations. It is a cross-sectional observational study that is unable to identify a clear cause–effect relationship. Additionally, the questionnaire could result in time, selection, recall, and reporting bias. At the same time, the timing of medication administration was unclear, which was a limitation of our study. However, this study included a large number of multicenter SLE patients, which helped avoid selection bias. Despite these limitations, the results of our study represent the current status of SLE patients in China. In conclusion, female SLE patients of childbearing age have a high proportion of menstrual abnormalities, APO, and ABO. Acknowledgements We would like to thank all the rheumatologists, gynecologists, and patients that participated in this study. We were especially grateful to an out-of-hospital patient management platform called “MIJIAN.” Funding This study was supported by grants from the research project from the Beijing Natural Science Foundation (No. 7192211) and China International Medical Foundation (No. Z-2018-40-2101).

Abstract:To the Editor: Antiphospholipid syndrome (APS) is a disorder characterized with thrombotic and obstetric events in patients with persistent positive antiphospholipid antibodies (aPL), including lupus anticoagulant (LA), anticardiolipin antibody (aCL), and anti-β2 glycoprotein-I antibody (anti-β2GPI). The clinical symptoms of APS include many non-thrombotic manifestations, also called extra-criteria manifestations, including thrombocytopenia, aPL nephropathy, livedo reticularis, valve heart disease, and neurological manifestations.[1] Previous study found primary obstetric APS patients with extra-criteria manifestations might have risk of developing thrombosis,[2] and certain aPL types correlated with non-criteria manifestations.[3] We conducted a retrospective study to analyze aPL-associated clinical phenotypes, especially extra-criteria manifestations. This study was approved by the Medical Ethics Committee of Peking Union Medical College Hospital. Signed informed consent was obtained from all patients. A total of 731 serum samples were tested for aPL during 2018 November and December, positive aPL samples were enrolled. Detection of LA was concurrent with the recommended criteria from the International Society on Thrombosis and Haemostasis. The aCL and anti-β2GPI antibodies were detected by enzyme-linked immunosorbent assay using commercially available kits. Definition of a moderate-to-high titer of aCL or anti-β2GPI antibody was 40 or more GPL or MPL units, and a low titer was 20 to 39 GPL or MPL units. Persistent was defined as tested on two or more occasions at least 12 weeks apart. The extra-criteria manifestations were defined as follows. Thrombocytopenia was defined as platelets level <100,000 mm3 on two occasions. Livedo reticularis was assessed by a dermatologist. aPL-associated nephropathy was diagnosed with renal biopsy. Valve heart disease was confirmed with echocardiogram. Neurological manifestations included migraines, seizures, chorea, longitudinal myelitis, and cognitive dysfunction in the absence of stroke, which were diagnosed by a neurologist. A total of 200 aPL positive patients were enrolled, 20 patients turned negative after 12 weeks, 180 were persistent. Among them, 131 were female and 49 male, the average age was 40.3 years old; 149 cases were anti-β2GP1 positive, 107 were aCL positive, 65 were LA positive, and 46 patients were triple aPL positive. 61 (33.9%) fulfilled the 2006 revised Sydney classification criteria for APS, 27 were primary and 34 were secondary. While thrombosis occurred in 44 (24.4%) patients and pregnant morbidity in 17 (9.4%), 119 (66.1%) patients were just persistent aPL positive only, 77 (42.8%) were totally asymptomatic, and 42 (23.3%) presented extra-criteria manifestations independently. Since there were also 30 APS patients with extra-criteria manifestations, the total frequencies of aPL associated extra-criteria manifestations were 40% (72/180). The most common extra-criteria manifestations were thrombocytopenia (31.7%), neurological manifestations (10.0%), and valve heart disease (8.3%), they were more common in Secondary APS compared with primary PAPS and non-APS-aPL+ patients [Table 1]. We compared aPL+ patients with and without extra-criteria manifestations and found that patients secondary to systemic lupus erythematosus (SLE) (47.2% vs. 24.1%, P = 0.002), with LA (50.0% vs. 26.9%, P = 0.002), moderate-to-high titer anti-β2GPI antibody (59.7% vs. 44.4%, P = 0.049), and triple aPLs (40.3% vs. 15.7%, P < 0.001) were more likely to present with extra-criteria manifestations. Table 1 - Prevalence of extra-criteria manifestations in persistent aPL-positive patients. Items All (n = 180) PAPS (n = 27) SAPS (n = 34) Non-APS aPL+ (n = 119) P values Female, n (%) 131 (72.8) 18 (66.7) 26 (76.5) 87 (73.1) 0.687 Age (years), mean (SD) 40.3 (17.6) 37.8 (11.0) 37.7 (15.4) 41.6 (19.4) 0.384 Anti-β2GPI antibody, n (%) 149 (82.8) 25 (92.6) 29 (85.3) 95 (79.8) 0.259 aCL, n (%) 107 (59.4) 18 (66.7) 24 (70.6) 65 (54.6) 0.175 LA, n (%) 65 (36.1) 13 (48.1) 17 (50) 35 (29.4) 0.032 Triple aPL+, n (%) 46 (25.6) 11 (40.7) 14 (41.2) 21 (17.6) 0.003 pt w/extra-criteria, n (%) 72 (40.0) 9 (33.3) 21 (61.8) 42 (35.3) 0.016 Thrombocytopenia, n (%) 57 (31.7) 6 (22.2) 18 (52.9) 33 (27.7) 0.011 Livedo reticularis, n (%) 3 (1.7) 0 (0) 2 (6.5) 1 (0.8) 0.151 APL nephrology, n (%) 6 (3.3) 2 (7.4) 4 (12.9) 0 (0) 0.001 Valve heart disease, n (%) 15 (8.3) 2 (7.4) 7 (20.6) 6 (5.0) 0.015 Neurological, n (%) 18 (10) 3 (11.1) 8 (23.5) 7 (5.9) 0.010 Fisher's exact test. aCL: Anticardiolipin antibody; aPL: Antiphospholipid antibody; Anti-β2GPI antibody: Anti-β2 glycoprotein I antibody; LA: Lupus anticoagulant; PAPS: Primary antiphospholipid syndrome; SD: Standard deviation; SPAP: Secondary antiphospholipid syndrome. The 2006 Sydney revised classification criteria for APS emphasize the presence of aPL as an essential component. Patients with autoimmune disease, thrombocytopenia, elevated activated partial thromboplastin time, false-positive syphilis test, thrombotic event, pregnancy complications, neurological manifestations were considered as suspected APS and might get aPL tested. In this study, only 27.4% sample was positive, >70% aPL tests ordered were not diagnostic, and 10% positive aPL was just transient. For persistent aPL-positive patients, only 38% were diagnosed with APS, which revealed >60% positive aPL were not due to APS. Even in 131 aPL positive patients with persistent moderate-to-high aPL profile, only 46.6% of patients fulfilled APS diagnosis. This reminds us that doctors need to order aPL tests based on sufficient clinical manifestations and view positive aPL dialectically. Although thrombotic and obstetric manifestations are the only clinical events included in the APS classification criteria, there are numerous extra-criteria manifestations commonly observed in APS.[4] The prevalence of thrombocytopenia in APS ranges from 16% to 53% and thrombocytopenia in PAPS increasingly appears to be predictive of other APS complications and a higher adjusted Global APS Score.[5] The prevalence of valve abnormalities in primary APS was 30%, in aPL-positive SLE patients, the prevalence ranged from 14% to 86%. Central nervous system non-thrombotic manifestations in APS include cognitive dysfunction, migraine, seizures, multiple sclerosis-like syndrome, transverse myelitis, movement disorders, and psychiatric symptoms; among them, migraine might be the most common symptom in 20% of APS patients, chorea and transverse myelitis are rare but recommended to be included into APS criteria.[4] In this study, we found extra-criteria manifestations were not rare in APS patients (49.2%) and aPL+ only patients (35.3%), the total frequency (40%) was even higher than thrombotic (24.4%) and pregnant morbidity (9.4%) in aPL-positive patients, and they could present independently. Our study was limited due to its retrospective, single-center design. However, the innovation is worthy of attention. Most studies focus on patients diagnosed with APS, we are interested in patients who get aPL tested, focus on the clinical manifestations associated with aPL, especially the extra-criteria manifestations. Single-center design ensured intact medical records and the consistency of diagnosis. We would like to have multiple centers, and we hope to do further studies on each extra-criteria manifestation. In conclusion, 40% aPL-positive patients presented with extra-criteria manifestations regardless of thrombotic or obstetric events, more common in SLE patients. The most common extra-criteria manifestation was thrombocytopenia. Funding This study was supported by grants from the Chinese National Key Technology R&D Program, Ministry of Science and Technology (Nos. 2021YFC2501305, 2021YFC2501306), Beijing Municipal Science and Technology Commission (No. Z201100005520022,23,25–27), CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2021-I2M-1-005). Conflicts of interest None.

Female patients with SLE-associated APS have a lower ovarian reserve than either PAPS or SLE patients

Role of Anti-Müllerian Hormone and Testosterone in Follicular Growth: a Cross-Sectional Study.

Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone

Risk Factors for Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome

Impact of Systemic Lupus Erythematosus on Ovarian Reserve in Premenopausal Women Before Receiving Cyclophosphamide Therapy: Evaluation Using Anti-Müllerian Hormone

Health-related quality of life impairment is equal for antiphospholipid syndrome whether primary or associated with systemic lupus erythematosus

A new insight into the impact of systemic lupus erythematosus on oocyte and embryo development as well as female fertility

Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis

Risk Factors for Pregnancy Morbidity in Women with Antiphospholipid Syndrome.

Ovarian reserve alteration in premenopausal women with systemic sclerosis

Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility

Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus

Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study

Diminished ovarian reserve associates with pregnancy and birth outcomes after IVF: a retrospective cohort study

Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome

Prevalence of premature ovarian failure in patients with systemic lupus erythematosus

Hematological Activity in Primary Antiphospholipid Syndrome: A Common Manifestation Outside the Classification Criteria

Clinical Features Associated with Pregnancy Outcomes in Women with Positive Antiphospholipid Antibodies and Previous Adverse Pregnancy Outcomes: a Real-World Prospective Study.

Menstrual irregularity, pregnancy outcomes, and birth outcomes in patients with systemic lupus erythematosus of childbearing age in China: a multicenter cross-sectional study

Extra-criteria Clinical Manifestations of Antiphospholipid Antibody Should Not Be Ignored

A Comparison of Obstetric Outcomes in Antiphospholipid Syndrome Among Pregnant Women With Systemic Lupus Erythematosus